Thursday 14 December 2017
Contact US    |    Archive
PR
2 months ago

Remetinostat Phase II Data Demonstrate Efficacy on Skin Lesions, Reduction of Itching and High Tolerability in Patients With Early-stage MF-type CTCL

STOCKHOLM, Oct. 13, 2017 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that ph

Read on the original site


Hashtags:   

Remetinostat

 | 

Phase

 | 

Data

 | 

Demonstrate

 | 

Efficacy

 | 

Skin

 | 

Lesions

 | 

Reduction

 | 
Most Popular (6 hours)

Most Popular (24 hours)

Most Popular (a week)

Categories - Countries
All News
All Countries